



STATUS OF THE CLAIMS

1. (currently amended) A composition comprising a drug-eluting stent media; wherein said drug-eluting stent media comprises a pharmaceutical composition; wherein said pharmaceutical composition comprises an agent, wherein said agent is comprising the following formula:



including both R and S enantiomeric forms and racemic mixtures;

wherein R1, R2, R3 and R4 are selected from the group consisting of:

hydrogen; CH₃; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein said aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain

~~having at least 2 carbons; wherein said aliphatic chain terminates with a carboxylic acid subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one amide subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one acyl group; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one nitrogen containing moiety; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one amine subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ether subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one halogen subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one nitronium subgroup;~~

~~wherein R5 is selected from the group consisting of: OH; NO₂; OR'; wherein~~

~~R' is selected from the group consisting of:~~

~~a linear or branched, saturated or unsaturated aliphatic chain having at least one carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxyl subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein said aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein said aliphatic chain terminates with a carboxylic acid subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one amide subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one acyl group; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least~~

~~one nitrogen-containing moiety; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one amine subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one halogen subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one nitronium subgroup; wherein R6 is selected from the group consisting of: Hyrdrogen; NO₂; Cl; F; Br; I; SR'; and NR'₂; wherein R' is defined as above in R5;~~

~~wherein R7 is selected from the group consisting of:~~

~~Hydrogen; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; and~~

~~wherein R8 is an aliphatic cyclic group larger than benzene; wherein said larger than benzene comprises any chemical group containing 7 or more non hydrogen atoms, and is an aryl or aliphatic cyclic group.~~

2-11. (canceled).

12. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media is in contact with a drug-eluting stent.

13. (previously presented) The composition of Claim 12, wherein said drug-eluting stent is seeded with endothelial cells.

14. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anticoagulant drug.

15. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an antiplatelet drug.

16. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an antimicrobial agent.

17. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anti-inflammatory agent.

18. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anti-metabolic agent.

19. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises a vasoreactive agent.

20. (previously presented) The composition of Claim 14, wherein said vasoreactive agent is a nitric oxide releasing agent.